

6th Knowledge Series for Genitourinary Cancers - Best of 2024 Day 1 - 17th May 2025 Venue - Courtyard by Marriott, Andheri, Mumbai		
Time	Topic	Faculty
08:00 - 08:50 AM	Registration & Networking	
08:50 - 09:00 AM	Introduction/Welcome Message	Dr. Puneet Ahluwalia, Delhi (UO)
	Session Coordinator:	UO & RO
	Session 1: Prostate Non-Metastatic	
	Chairpersons:	Dr. N P Gupta, Gurugram (UO) Dr. Amlesh Seth, Delhi (UO) Dr. Nitin Kekre, Vellore (UO) Dr. V Kannan, Mumbai (RO)
09:00 - 09:10 AM	1. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study 2. Prospective Clinical Implementation of Paige Prostate Detect Artificial Intelligence Assistance in the Detection of Prostate Cancer in Prostate Biopsies: CONFIDENT P Trial Implementation of Artificial Intelligence Assistance in Prostate Cancer Detection	Dr. Harshit Garg, Delhi (UO)
09:10 - 09:17 AM	Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy	Dr. Ashish Khanna, Delhi (UO)
09:17 - 09:24 AM	Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial	Dr. Srivatsan Ramani, Chennai (UO)
09:24 - 09:31 AM	Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective, Single-Arm Trial	Dr. Shashank Agrawal, Hyderabad (UO)
09:31 - 09:38 AM	Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer NEJM 2024	Dr. Renu Madan, Chandigarh (RO)
09:38 - 09:45 AM	Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial,Radiotherapy and Oncology 2024	Dr. Bhavin Visariya, Mumbai (RO)
09:45 - 09:52 AM	Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial	Dr. Dipalee Borade, Mumbai (RO)
09:52 - 10:00 AM	Expert Comments	By Chairperson
10:00 - 10:30 AM	Panel Discussion on above abstracts	
	Moderator:	Dr. Sanjoy Sureka, Lucknow (UO)
	Panelist	Dr. Kinju Adhikari, Bangalore (UO)
	Panelist	Dr. Hemang Baxi, Ahmedabad (UO)
	Panelist	Dr. Tarun Jindal, Kolkata/Dr. Neeraj Agarwal, Jaipur (UO)
	Panelist	Dr. Mahendra Pal, Mumbai (UO)
	Panelist	Dr. Brusabhanu Nayak, Delhi (UO)
	Panelist	Dr. Arabind Panda, Hyderabad (UO)
	Panelist	Dr. Abhishek Singh, Nadiad (UO)
	Panelist	Dr. Trinanjan Basu, Mumbai (RO)
	Panelist	Dr. Ram Alva, Bengaluru (RO)
10:30 - 10:40 AM	Take Home Message	Dr. Shashank Agrawal, Hyderabad (UO) Dr. Gagandeep Talwar, Gurugram (UO)
	Session Coordinator:	TBD
	Session 2: Prostate Non-Metastatic	
	Chairpersons:	Dr. Anil Mandhani, Gurugram (UO) Dr. Nitin Kekre, Vellore (UO) Dr. Sharmila Agarwal, Mumbai (RO) Dr. Rajendra Bhalavat, Mumbai (RO)
10:40 - 10:47 AM	Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection	Dr. Ravi Taori, Bengaluru (UO)
10:47 - 10:57 AM	1. Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial 2. Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial	Dr. Shyam Mohan, Mumbai (UO)
10:57 - 11:04 AM	Re-SBRT after previous definitive or salvage radiotherapy (RE-START). A study on behalf of AIRO.	Dr. Sagar Gayakwad, Dombivli (RO)

11:04 - 11:11 AM	Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.European Urology 2024	Dr. Sayan Das, Kolkata (RO)
11:11 - 11:18 AM	Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs). ASCO-GU 2025 abstract no.309	Dr. Ankita Rungta Kapoor, Varanasi (RO)
11:18 - 11:25 AM	<u>ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer</u>	Dr. Amit Kumar, Patna (MO)
11:25 - 11:32 AM	Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer	Dr. Sayan Paul, Kolkata (RO)
11:32 - 11:42 AM	Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. PORTOS gene signature as a predictor of risk of adverse events after doseescalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126. Karen E. Hoffman, Sophia C. Kamran, Hyunnam Monica Ryu, James A. Proudfoot, Ela	Dr. Vikas Kothavade, Pune (RO)
11:42 - 11:45 AM	Expert Comments	By Chairperson
11:45 AM - 12:15 PM	Panel Discussion on above abstracts	
	Moderator:	Dr. Sujana Priya, Hyderabad (RO)
	Panelist	Dr. Kanhu Charan Patro, Visakhapatnam (RO)
	Panelist	Dr. Vivek Anand, Mumbai (RO)
	Panelist	Dr. Rohit Malde, Mumbai (RO)
	Panelist	Dr. Manish Chandra, Mumbai (RO)
	Panelist	Dr. Amit Kumar, Patna (MO)
	Panelist	Dr. Aditya Pradhan, Delhi (UO)
	Panelist	Dr. Gaurav Kumar, Muzaffarpur (MO)
	Panelist	Dr. Yuvaraja T B, Mumbai (UO)
12:15 - 12:25 PM	Take Home Message	Dr. Sharmila Agarwal, Mumbai (RO)
	Session Coordinator:	Dr. Akhil Kapoor, Varanasi (MO) Dr. Aditya Dhanawat, Mumbai (MO)
	Session 3: Prostate Metastatic	
	Chairpersons:	Dr. Amit Joshi, Mumbai (MO) Dr. Shyam Shrivastava, Mumbai (RO)
12:25 - 12:32 PM	Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial	Dr. Aditya Dhanawat, Mumbai (MO)
12:32 - 12:39 PM	ASCO GU 2025: Which Patients with mHSPC Benefit More from Androgen Receptor Pathway Inhibitors? STOPCAP Meta-Analyses of Individual Participant Data	Dr. Sunil Chopade, Mumbai (MO)
12:39 - 12:46 PM	ASCO 2024: PLATIPARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients with mCRPC with Homologous Recombination DNA Repair Deficiency	Dr. Suparna Rao, Mumbai (MO)
12:46 - 12:53 PM	ASCO GU25 Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).	Dr. Atul Narayankar, Mumbai (MO)
12:53 - 01:00 PM	ASCO GU25 Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer.	Dr. Pooja Gupta, Delhi (MO)
01:00 - 01:10 PM	Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study	Dr. Sayak Choudhury, Mumbai (NM)
01:10 - 01:17 PM	ASCO GU25 A prospective trial of a structured exercise program to lessen fatigue in patients with advanced prostate cancer (aPC) undergoing androgen deprivation therapy (ADT).	Dr. Prahalad Elamarthi, Bengaluru (MO)
01:17 - 01:24 PM	Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). ASCO-GU 2025 abstract no.22	Dr. Deepanjali Adulkar, Mumbai (RO)
01:24 - 01:31 PM	Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study	Dr. Prahlad Yathiraj, Chennai (RO)
01:31 - 01:40 PM	Expert Comments	By Chairperson
01:40 - 02:10 PM	Panel Discussion on above abstracts	
	Moderator:	Dr. Atul Batra, Delhi (MO)
	Panelist	Dr. Prahalad Elamarthi, Bengaluru (MO)
	Panelist	Dr. Sudeep Das, Kolkata (MO)

	Panelist	Dr. Niharika Alapati, Vizag (MO)
	Panelist	Dr. Virender Suhag, Delhi (RO)
	Panelist	Dr. Madan Maitre, Mumbai (RO)
	Panelist	Dr. Indrāja Dev, Mumbai (NM)
	Panelist	Dr. Arvind Suresh, Varanasi (NM)
02:10 - 02:20 PM	Take Home Message	1 MO 1 RO
02:20 - 02:50 PM	Lunch	
02:50 - 03:20 PM	Sponsored Session by Astellas	
	Session Coordinator:	Dr. Saurabh Patil, Mumbai (UO)
	Session 4: Renal Cell Carcinoma	
	Chairpersons:	Dr. Sudhir Kumar Rawal, Delhi (UO) Dr. Jagdeesh N. Kulkarni, Mumbai (UO) Dr. Anant Kumar, Delhi (UO)
03:20 - 03:27 PM	[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	Dr. Shrikanth Atluri, Mumbai (UO)
03:27 - 03:34 PM	Comparative efficacy of cryoablation versus robot-assisted partial nephrectomy in the treatment of cT1 renal tumors: a systematic review and meta-analysis	Dr. Anuj Sharma, Mumbai (UO)
03:34 - 03:41 PM	Relevance of Positive Surgical Margins in Localized Renal Cell Carcinoma After Surgical Resection: Predictive Factors and Survival Implications	Dr. Uday Chandankhede, Nagpur (UO)
03:41 - 03:48 PM	Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. DOI: 10.1056/NEJMoa2312695	Dr. Sudeep Das, Kolkata (MO)
03:48 - 03:55 PM	NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus	Dr. Deep Vora, Mumbai (MO)
03:55 - 04:00 PM	Expert Comments	By Chairperson
04:00 - 04:30 PM	Panel Discussion on above abstracts	
	Moderator:	Dr. Srivatsa N, Bengaluru (UO)
	Panelist	Dr. Santosh Kumar, Chandigarh (UO)
	Panelist	Dr. Ganesh Bakshi, Mumbai (UO)
	Panelist	Dr. Kishore T A, Kochi (UO)
	Panelist	Dr. Ankur Mittal, Rishikesh (UO)
	Panelist	Dr. Deep Vora, Mumbai (MO)
	Panelist	Dr. Alok Kumar Goel, Sangrur (MO)
	Panelist	Dr. Indrāja Dev, Mumbai (NM)
04:30 - 04:40 PM	Take Home Message	Dr. Mayank Agrawal, Gurugram (UO)
04:40 - 05:20 PM	Sponsored Session 2	
	Session Coordinator:	Dr. Nandini Menon, Mumbai (MO) Dr. Athira Surendran, Mumbai (MO)
	Session 5: Metastatic RCC	
	Chairpersons:	Dr. Randeep Singh, Delhi (MO) 1 UO Dr. Wasim Phoplunkar, Mumbai (RO)
05:20 - 05:27 PM	Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis	Dr. Ajit Gujela, Mumbai (UO)
05:27 - 05:34 PM	Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC. ASCO-GU 2025	Dr. Sweetey Gupta, Rishikesh (RO)
05:34 - 05:41 PM	ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO)	Dr. Karan Sood, Wardha (MO)
05:41 - 05:48 PM	Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Annals of Oncology	Dr. Kishore Kumar Kota, Vishakapatnam (MO)
05:48 - 05:55 PM	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO OPEN	Dr. Pritesh Munot, Mumbai (MO)
05:55 - 06:02 PM	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Annals of Oncology	Dr. Amit Kumar, Patna (MO)

06:02 - 06:10 PM	Expert Comments	By Chairperson
06:10 - 06:40 PM	Panel Discussion on above abstracts	
	Moderator:	Dr. Vijay Patil, Mumbai (MO)
	Panelist	Dr. Yashwant Kashyap, Raipur (MO)
	Panelist	Dr. Rohit Pai, Mumbai (MO)
	Panelist	Dr. Sudeep Das, Kolkata (MO)
	Panelist	Dr. Wasim Phoplunkar, Mumbai (RO)
	Panelist	Dr. Tanweer Shahid, Kolkata (RO)
	Panelist	Dr. Sayak Choudhury, Mumbai (NM)
	Panelist	Dr. Keval Patel, Ahmedabad (UO)
	Panelist	Dr. Prasant Nayak, Bhubaneswar (UO)
06:40 - 06:50 PM	Take Home Message	1 MO 1 RO
06:50 - 07:10 PM	Sponsored Session 3	
07:10 - 07:30 PM	Sponsored Session 4	
	“Reshaping Patient Ecosystem in Bladder cancer: A multistakeholder perspective”	TBD
07:30 - 08:00 PM	Quiz for Residents	
08:00 PM Onwards	Closing Remarks Followed by Dinner	Dr. Ashay Karpe, Mumbai (MO)

6th Knowledge Series for Genitourinary Cancers - Best of 2024 Day 2 - 18th May 2025 Venue - Courtyard by Marriott, Andheri, Mumbai		
Time	Topic	Faculty
08:55 - 09:00 AM	Welcome and Introduction	Dr. Aditi Aggarwal, Gurugram (RO)
	Session Coordinator:	Dr. Aditi Aggarwal, Gurugram (RO)
	Session 1: Urothelial Cancer Part I	
	Chairpersons:	Dr. Ravindra B Sabnis, Nadiad (UO) Dr. Mallikarjun Kalashetty, Bangalore (UO) 1 MO Dr. Sweetly Gupta, Rishikesh (RO)
09:00 - 09:07 AM	Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.Journal of Clinical Oncology. https://doi.org/10.1200/JCO.23.02398	Dr. Rahul Jena, Bhubaneswar (UO)
09:07 - 09:17 AM	Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. https://doi.org/10.1111/bju.16509	Dr. Amandeep Arora, Mumbai (UO)
09:17 - 09:24 AM	Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection	Dr. Ravi Chandran K, Bengaluru (UO)
09:24 - 09:31 AM	Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. https://doi.org/10.1200/JCO.23.02510	Dr. Nikhil Kalyani, Mumbai (RO)
09:31 - 09:38 AM	Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)	Dr. Athira Surendran, Mumbai (MO)
09:38 - 09:45 AM	Sheng X, Zhang C, Ji Y, et al. Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. J Clin Oncol 43, 2025	Dr. Nagendra Sharma, Delhi (MO)
09:45 - 09:52 AM	Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy	Dr. Shyam Mohan, Mumbai (UO)
09:52 - 09:59 AM	Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer	Dr. Akash Shah, Mumbai (UO)
09:59 - 10:06 AM	Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial.ASTRO 2024 / IJROBP full paper. doi:10.1016/j.ijrobp.2024.09.040	Dr. Priyamvada Maitre, Mumbai (RO)
10:06 - 10:16 AM	Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. European Urology 2024. https://doi.org/10.1016/j.eururo.2024.09.006	Dr. Parth Verma, Surat (RO)

	Hypofractionated chemoradiotherapy for bladder preservation in muscle-invasive bladder cancer. ESTRO 2024	
10:16 - 10:25 AM	Expert Comments	By Chairperson
10:25 - 10:55 AM	Panel Discussion on above abstracts	
	Moderator:	Dr. Sanjai Addla, Hyderabad (UO)
	Panelist	Dr. N. Ragavan, Chennai (UO)
	Panelist	Dr. Ginil Kumar P, Kochi (UO)
	Panelist	Dr. Bhalchandra Kashyapi, Pune (UO)
	Panelist	Dr. Anand Raja, Chennai (UO)
	Panelist	Dr. Priyamvada Maitre, Mumbai (RO)
	Panelist	Dr. Kaustav Talapatra, Mumbai (RO)
	Panelist	Dr. Nagendra Sharma, Delhi (MO)
	Panelist	Dr. Amit Kumar, Patna (MO)
10:55 - 11:00 AM	Take Home Message	UO
	Session Coordinator:	Dr. Arvind Vaidyanathan, Mumbai (MO) Dr. Srigantha Vivek Kumar, Mumbai (MO)
	Session 2: Urothelial Cancer Part II	
11:00 - 11:20 AM	Sponsored Session 1	
11:20 - 11:40 AM	Sponsored Session 2	
11:40 AM - 12:10 PM	Sponsored Session 3	
	Chairpersons:	Dr. Nagraj Huilgol, Mumbai (RO)
12:10 - 12:17 PM	Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer.ASTRO 2024. 220Volume 120, Issue 2, Supplement S74October 01, 2024 https://www.redjournal.org/issue/S0360-3016(24)X0011-5	Dr. Shantanu Pendse, Nagpur (MO)
12:17 - 12:27 PM	Efficacy of neoadjuvant/induction (NAC) chemotherapy in nonmetastatic muscleinvasive bladder cancer treated with chemoradiotherapy (CRT): A systematic review and meta-analysis. Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). Meghan Elizabeth Mahoney, N	Dr. Pooja Nandwani Patel, Ahmedabad (RO)
12:27 - 12:37 PM	ASCO GU25 Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. https://doi.org/10.1200/JCO.23.01659	Dr. Srigantha Vivek Kumar, Mumbai (MO)
12:37 - 12:44 PM	Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial	Dr. Arnav Tongaonkar, Mumbai (MO)
12:44 - 12:54 PM	Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)	Dr. MV Chandrakanth, Kolkata (MO)
12:54 - 01:00 PM	Expert Comments	By Chairperson
01:00 - 01:30 PM	Panel Discussion on above abstracts	
	Moderator:	Dr. Adwaita Gore, Mumbai (MO)
	Panelist	Dr. MV Chandrakanth, Kolkata (MO)
	Panelist	Dr. Shantanu Pendse, Nagpur (MO)
	Panelist	Dr. Sumit Basu, Mumbai (RO)
	Panelist	Dr. V Kannan, Mumbai (RO)
	Panelist	Dr. Srigantha Vivek Kumar, Mumbai (MO)
	Panelist	Dr. Arnav Tongaonkar, Mumbai (MO)
01:30 - 01:40 PM	Take Home Message	
01:40 - 02:10 PM	Sponsored Session 4	
02:10 - 02:30 PM	Quiz for Residents	
02:30 PM Onwards	Closing Remarks Followed by Lunch	Dr. Kumar Prabhash, Mumbai (MO)